Extension Study of ABP-671 in Participants With Gout

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

September 5, 2024

Study Completion Date

September 5, 2024

Conditions
Gout
Interventions
DRUG

ABP-671

"Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study.~Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study."

DRUG

Allopurinol

Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.

Trial Locations (54)

833

Chang Gung Memorial Hospital CGMH, Kaohsiung City

2019

Emeritus Research Sydney, Botany

2148

Paratus Clinical Research Western Sydney, Blacktown

2259

Paratus Clinical Research Central Coast, Kanwal

3084

Austin Health - Repatriation Hospital, Heidelberg

3124

Emeritus Research Melbourne, Camberwell

4021

A R Houston Medical Pty Ltd, Kippa-Ring

16635

Altoona Center for Clinical Research, Duncansville

21401

Annapolis Internal Medicine/CCT Research, Annapolis

28144

OnSite Clinical Solutions, Salisbury

30309

Advanced Clinical Research of Atlanta, Atlanta

31904

Centricity Research, Columbus

32216

Jacksonville Center for Clinical Research, Jacksonville

32720

Accel Clinical Research Site, DeLand

32807

Combined Research Orlando Phase I-IV, Orlando

33135

A & D Doctor Center, Miami

33155

Bioclinical Research Alliance, Miami

Cordova Research Institute, Miami

33158

New Horizons Research, Palmetto Bay

33173

Century Research LLC, Miami

ITB Research, Miami

33189

JY Research Institute Inc., Cutler Bay

34429

Nature Coast Clinical Reasearch, Crystal River

34613

Access Research Institute, Brooksville

37421

ClinSearch, Chattanooga

37643

Medical Care/CCT, Elizabethton

39501

DelRicht Research of Gulfport, Gulfport

62247

Buddhist Dalin Tzu Chi General Hospital, Chiayi City

67114

Alliance for Multispecialty Research, LLC., Newton

68114

Quality Clinical Research, Inc, Omaha

70115

DelRicht Research, New Orleans

70119

AMR, New Orleans

78209

Quality Research Inc., San Antonio

78217

Worldwide Clinical Trials, San Antonio

78520

PanAmerican Clinical Research, LLC, Brownsville

85281

Alliance for Multispecialty Research, Tempe

85710

Tucson Neuroscience Research, LLC, Tucson

87505

Inspire Santa Fe Medical Group, Santa Fe

89119

Santa Rosa Medical Center, Las Vegas

92801

Anaheim Clinical Trials (Cenexel ACT), Anaheim

95823

Center for Clinical Trials of Sacramento, Sacramento

112401

Cheng-Shin General Hospital, Taipei

333423

Chang Gung Memorial Hospital LinKou, Taoyuan District

402367

Chung Shan Medical Univ. Hospital, Taichung

0114

New Hospitals, Tbilisi

0159

Evex Hospitals Caraps Medline, Tbilisi

0160

Aversi Clini, Tbilisi

0180

The First Medical Center, Tbilisi

0186

Academician Vakhtang Bochorishvili Clinic, Tbilisi

Innova, Tbilisi

01010

Clinical Research Center (CRC), Guatemala City

Clínica Médica Especializada en Medicina Interna y Reumatología (CREER), Guatemala City

Clínica Médica Especializada en Medicina Interna y Reumatología, Guatemala City

Clínica Médica Especializada en Medicina Interna, Guatemala City

Sponsors
All Listed Sponsors
lead

Atom Therapeutics Co., Ltd

INDUSTRY

NCT06276556 - Extension Study of ABP-671 in Participants With Gout | Biotech Hunter | Biotech Hunter